Under Consideration

Vertex Pharmaceuticals' cystic fibrosis drug, Orkambi, goes in front of a US Food and Drug Administration advisory committee this week, the Wall Street Journal reports.

The drug is being targeted to patients with cystic fibrosis patients who have a certain genetic mutation. Vertex also makes the cystic fibrosis drug Kalydeco.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.